HDAC10 and chronic myelogenous leukemia, BCR-ABL1 positive: The effects following RNAi-mediated HDAC10 depletion could be confirmed using the commercially purchased near-haploid chronic myeloid leukemia (CML) HDAC10 knockout cell line (HAP1 HDAC10 KO), which accumulated slightly but significantly (p = 9.8 ∗ 10−5) higher amounts of doxorubicin than their HDAC10 expressing wild type counterpart (HAP1 wt) (Fig. 3e,f).